Skip to main content
RANI logo

Rani Therapeutics Holdings, Inc. (RANI) Stock Price & Analysis

Rani Therapeutics Holdings, Inc. (RANI) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $0.6481 (+15.86%), as of the Nov 18, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.6481 +$0.0887 (+15.86%)

Rani Therapeutics Holdings, Inc. · RANI · NASDAQ

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics using its RaniPill capsule technology. The company aims to replace subcutaneous or IV injections with oral dosing for various therapeutic areas.

Price as of Nov 18, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Rani Therapeutics Holdings (RANI)

Weak
Business Quality Poor (17)
Financial Safety Sound (63)
Valuation Bubble (16)
Growth Durability Growing (63)
Momentum Slipping (30)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Bubble; Growth Durability: Growing; Momentum: Slipping.

  • EPS beat 0 of the last 3 reports
  • Altman Z -3.32 · Piotroski F 5
  • ROE -96.4% · ROA -61.8% · current ratio 5.26 · earnings yield -30.2% · free-cash-flow yield -65.8%

Holding back: weak fundamentals, a rich price, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RANI (57 recorded, newest six shown)
RecordedScoreBand
21Weak
21Weak
21Weak
21Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$0.6481
Change on the day+15.86%
Shares traded on the day1.20M

Price & events

Other perspectives

Council score for Rani Therapeutics Holdings (RANI): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Moderate
Valuation Negative
Growth Durability Moderate
Momentum Weak

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Rani Therapeutics Holdings (RANI), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rani Therapeutics Holdings, Inc. (RANI) is listed on NASDAQ. It employs 69 people.

2 · Latest results

What do the latest results show for Rani Therapeutics Holdings (RANI)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 3 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$2M-$8M-$0.04 (diluted)
Q2 FY2026$2M-$7M-$0.04 (diluted)
Q1 FY2026$2M-$7M-$0.04 (diluted)
Q4 FY2025$1M-$10M-$0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Rani Therapeutics Holdings (RANI)?

Short answer · as of

What is holding it back is weak fundamentals, a rich price, weak price trend. The distress and quality screens read Altman Z -3.32 · Piotroski F 5. Trailing ratios: ROE -96.4% · ROA -61.8% · current ratio 5.26 · earnings yield -30.2% · free-cash-flow yield -65.8%.

Data-derived red flags

  • Listing risk — at $0.6481 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -3.32 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-96.4%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does Rani Therapeutics Holdings compare with its peers?

Short answer

Rani Therapeutics Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Named competitor$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
Novo Nordisk A/S (NVO) Named competitor$39.43 Nov 18, 2026$174B87 5-pillar Nov 18, 2026
Rani Therapeutics Holdings (RANI) — this page$0.6481—21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RANI in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RANI in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: RANI Stock

These answers are editorial: 1 of these 9 answers is drawn from the RANI research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for RANI?

RANI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is RANI a good stock to buy?

Stock Expert AI does not rate RANI buy, sell or hold. Rani Therapeutics Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RANI stock price today?

The last price recorded for Rani Therapeutics Holdings, Inc. (RANI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about RANI stock?

Analyst coverage of Rani Therapeutics Holdings, Inc. is still emerging, reflecting its clinical-stage status. Key valuation metrics focus on the potential of the RaniPill technology and the success of its clinical trials.

What are the key factors to evaluate for RANI?

Rani Therapeutics Holdings, Inc. (RANI) holds a MoonshotScore in the low range. This would provide the company with additional funding and expertise, while also expanding its market reach. Not financial advice.

How frequently does RANI data refresh on this page?

RANI's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RANI's recent stock price performance?

Rani Therapeutics Holdings, Inc. (RANI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative RaniPill capsule technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RANI overvalued or undervalued right now?

Rani Therapeutics Holdings, Inc. (RANI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of RANI?

Fractional-share availability for Rani Therapeutics Holdings, Inc. (RANI) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 9 figures on this page — 6 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.